Retrospective evaluation of hairy cell leukemia patients treated with three different first-line treatment modalities in the last two decades: A single-center experience Geçmiş ıki dekatta üç farklı birinci basamak tedavisi alan tüylü hücreli lösemi hastalarının geriye dönük değerlendirmesi: Tek merkez deneyimi


ÖNGÖREN Ş., EŞKAZAN A. E., Berk S., ELVERDİ T., SALİHOĞLU A., AR M. C., ...Daha Fazla

Turkish Journal of Hematology, cilt.34, sa.4, ss.291-299, 2017 (SCI-Expanded, Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 34 Sayı: 4
  • Basım Tarihi: 2017
  • Doi Numarası: 10.4274/tjh.2016.0443
  • Dergi Adı: Turkish Journal of Hematology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.291-299
  • Anahtar Kelimeler: Cladribine, Hairy cell leukemia, Interferon, Splenectomy
  • Sağlık Bilimleri Üniversitesi Adresli: Hayır

Özet

Objective: In this study, we retrospectively analyzed the clinical outcome, treatment responses, infectious complications, and survival rates of 71 hairy cell leukemia (HCL) cases. Materials and Methods: Sixty-seven patients received a first-line treatment and 2-chlorodeoxyadenosine (cladribine-2-CdA) was administered in 31 cases, 19 patients received interferon-alpha (INF-α), splenectomy was performed in 16 cases, and rituximab was used in one. Results: Although the highest overall response rate (ORR) was observed in patients receiving 2-CdA upfront, ORRs were comparable in the 2-CdA, INF-α, and splenectomy subgroups. Relapse rates were significantly lower in patients who received first-line 2-CdA. The progression-free survival (PFS) rate with 2-CdA was significantly higher than in patients with INF-α and splenectomy, but we found similar overall survival rates with all three upfront treatment modalities. Infections including tuberculosis were a major problem. Conclusion: Although purine analogues have improved the ORRs and PFS, there is still much progress to make with regard to overall survival and relapsed/refractory disease in patients with HCL.